Ofloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ofloxacin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Ofloxacin is a fluoroquinolone antibacterial. The registration data we hold does not list its approved indications, so the original use here is taken from the drug class. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but 0 clinical trials and 0 publications support this prediction. It is a knowledge-graph prediction only, with no plausible mechanism behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the available SAHPRA registration data (fluoroquinolone antibacterial by drug class) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
It is not, on current evidence. Detailed mechanism of action data is not available in the Evidence Pack. Ofloxacin is known to inhibit bacterial DNA gyrase and topoisomerase IV, which is how it kills bacteria.
Polyclonal hyperviscosity syndrome involves raised serum viscosity from excess immunoglobulins. Ofloxacin has no known effect on serum viscosity or immunoglobulin levels, so no mechanistic link can be drawn. The very high TxGNN score (99.91%, rank 754) reflects a pattern in the knowledge graph, not any demonstrated therapeutic effect.
Clinical Trial Evidence
Currently no related clinical trials registered. This includes ClinicalTrials.gov, ICTRP, SANCTR and PACTR.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. A39/20.1.1/0149 | Ofloxacin 200 mg austell | Tablet (oral) | Not stated in the registration data |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Fluoroquinolones as a class carry a known peripheral neuropathy warning. This matters if the drug were considered for haematological conditions associated with neuropathy.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trials, no literature and no plausible mechanism, so it stays at evidence level L5. The SAHPRA safety information is also missing, which blocks safety screening.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications and approved indications)
- Mechanism of action data from DrugBank
- A credible mechanistic rationale and at least preclinical evidence for polyclonal hyperviscosity syndrome
Note on other predictions for this drug: Of the ten predicted indications, septicemic plague (rank 8) is the most biologically plausible. It has L4 evidence: a 2002 experimental plague study of ofloxacin, plus animal-model and class-level fluoroquinolone data. It extends the known antibacterial spectrum rather than being a novel repurposing, and it remains a research question, not a clinical recommendation.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.